A Phase 1b Open-Label, Multi-Center Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With High-Risk Stage I and Stages II-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

Trial Profile

A Phase 1b Open-Label, Multi-Center Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With High-Risk Stage I and Stages II-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Trebananib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 17 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jan 2015 Planned End Date changed from 1 Jan 2015 to 1 Mar 2015 according to ClinicalTrials.gov record.
    • 08 Oct 2014 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top